United Therapeutics Corporation logo
United Therapeutics Corporation (UTHR)
Compare

United Therapeutics Corporation (UTHR) PE Ratio: 20.18

popular:market cap|pe ratio|revenue|price history|total return

Is United Therapeutics Corporation’s P/E ratio high or low?

United Therapeutics Corporation's P/E ratio of 20.18 is 26% above its 5-year average of 16.04, near the high end of its 5-year range (10.72–22.06).

As of Saturday, June 13, 2026. 18.22% above its 12-month average of 17.07.

PE Ratio (20.18) = Close Price ($545.96) / Diluted TTM EPS ($27.05)

PEG Ratio|P/B Ratio|EPS|All Metrics

UTHR PE Ratio Chart

UTHR PE Ratio
20.18+76.71% 1Y
Zoom

UTHR Average PE Ratio Chart

UTHR Current vs Average PE Ratio Chart

UTHR PE Ratio Metrics

PE RATIO

20.18

PE RATIO AVG TTM

17.07

PE RATIO AVG 3Y

14.94

PE RATIO AVG 5Y

16.04

PE RATIO AVG 10Y

13.66

PE RATIO AVG 15Y

16.18

PE RATIO AVG 20Y

23.55

CURRENT VS TTM AVG

+18.22%

CURRENT VS 3Y AVG

+35.10%

CURRENT VS 5Y AVG

+25.78%

CURRENT VS 10Y AVG

+47.68%

CURRENT VS 15Y AVG

+24.70%

CURRENT VS 20Y AVG

-14.32%

UTHR Competitors' PE Ratio

NAMEMARKET CAPPE RATIOTTM3Y5Y
United Therapeutics Corporation (UTHR)$23.17B20.1817.0714.9416.04
Waters Corporation (WAT)$23.17B45.1832.0230.9630.45
BioNTech SE (BNTX)$22.90BN/A55.7322.6282.47
Mettler-Toledo International Inc. (MTD)$22.86B26.4931.9732.7836.41
Labcorp Holdings Inc. (LH)$21.83B23.5727.2032.1523.40
Veeva Systems Inc. (VEEV)$25.92B28.4446.8454.5866.72
Moderna, Inc. (MRNA)$19.80BN/A15.4632.5132.51
DexCom, Inc. (DXCM)$29.08B32.2141.7671.44113.43
Hologic, Inc. (HOLX)$16.97B31.6728.1230.0822.83
Biogen Inc. (BIIB)$29.53B21.4216.5918.5018.66

P/E vs. its own history

At 20.2, P/E is richer than usual, sitting higher than 66% of its 20-year history.

20-year low

5.4

median

16.3

20-year high

170.3

cheaperricher

P/E Comparison

Trailing P/E

20.2

Forward P/E

16.5

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$545.96

÷

Forward EPS (Est.)

$33.12

=

Forward P/E

16.48

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

United Therapeutics Corporation PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

United Therapeutics Corporation PE Ratio FAQ

What is the P/E ratio for United Therapeutics Corporation (UTHR)?
The P/E ratio for UTHR stock is 20.18.
Is United Therapeutics Corporation's P/E ratio high or low?
United Therapeutics Corporation's P/E ratio of 20.18 is 26% above its 5-year average of 16.04, near the high end of its 5-year range (10.72–22.06).
What is the TTM average P/E ratio for United Therapeutics Corporation (UTHR)?
The TTM average P/E ratio for UTHR stock is 17.07.
What is the 3Y average P/E ratio for United Therapeutics Corporation (UTHR)?
The 3Y average P/E ratio for UTHR stock is 14.94.
What is the 5Y average P/E ratio for United Therapeutics Corporation (UTHR)?
The 5Y average P/E ratio for UTHR stock is 16.04.
What is the 10Y average P/E ratio for United Therapeutics Corporation (UTHR)?
The 10Y average P/E ratio for UTHR stock is 13.66.
What is the 15Y average P/E ratio for United Therapeutics Corporation (UTHR)?
The 15Y average P/E ratio for UTHR stock is 16.18.
What is the 20Y average P/E ratio for United Therapeutics Corporation (UTHR)?
The 20Y average P/E ratio for UTHR stock is 23.55.

United Therapeutics Corporation PE Ratio History

DATEPE RATIO
2026-06-1220.18
2026-06-1120.16
2026-06-1020.11
2026-06-0920.45
2026-06-0820.14
2026-06-0520.33
2026-06-0420.25
2026-06-0320.31
2026-06-0219.96
2026-06-0120.13
2026-05-2920.58
2026-05-2820.78
2026-05-2721.10
2026-05-2621.38
2026-05-2221.01
2026-05-2120.92
2026-05-2020.85
2026-05-1920.95
2026-05-1820.96
2026-05-1521.02
2026-05-1421.29
2026-05-1321.42
2026-05-1221.51
2026-05-1121.07
2026-05-0820.89
2026-05-0721.04
2026-05-0622.06
2026-05-0520.54
2026-05-0420.86
2026-05-0120.47
2026-04-3020.51
2026-04-2920.50
2026-04-2820.43
2026-04-2720.35
2026-04-2420.36
2026-04-2320.56
2026-04-2220.61
2026-04-2120.58
2026-04-2020.58
2026-04-1721.12
2026-04-1620.84
2026-04-1520.73
2026-04-1420.77
2026-04-1320.73
2026-04-1020.52
2026-04-0920.63
2026-04-0820.88
2026-04-0720.31
2026-04-0620.09
2026-04-0220.27
2026-04-0120.47
2026-03-3121.28
2026-03-3021.12
2026-03-2718.77
2026-03-2619.11
2026-03-2519.44
2026-03-2419.09
2026-03-2318.71
2026-03-2018.82
2026-03-1918.92
2026-03-1819.04
2026-03-1719.38
2026-03-1619.18
2026-03-1319.24
2026-03-1219.12
2026-03-1119.55
2026-03-1019.23
2026-03-0918.99
2026-03-0617.16
2026-03-0517.41
2026-03-0417.60
2026-03-0317.90
2026-03-0218.44
2026-02-2718.09
2026-02-2618.08
2026-02-2519.21
2026-02-2417.94
2026-02-2317.98
2026-02-2017.94
2026-02-1918.21
2026-02-1818.04
2026-02-1718.28
2026-02-1317.95
2026-02-1218.04
2026-02-1118.03
2026-02-1017.93
2026-02-0917.93
2026-02-0618.39
2026-02-0518.15
2026-02-0418.29
2026-02-0318.12
2026-02-0218.00
2026-01-3017.79
2026-01-2917.72
2026-01-2817.71
2026-01-2718.07
2026-01-2617.94
2026-01-2317.77
2026-01-2217.89
2026-01-2117.80
2026-01-2017.74
2026-01-1617.62
2026-01-1517.89
2026-01-1418.03
2026-01-1318.07
2026-01-1218.28
2026-01-0918.31
2026-01-0818.60
2026-01-0719.09
2026-01-0619.05
2026-01-0518.56
2026-01-0218.82
2025-12-3118.46
2025-12-3018.80
2025-12-2919.06
2025-12-2619.22
2025-12-2419.50
2025-12-2319.34
2025-12-2219.47
2025-12-1919.60
2025-12-1819.21
2025-12-1719.36
2025-12-1618.95
2025-12-1518.96
2025-12-1218.72
2025-12-1118.51
2025-12-1018.37
2025-12-0918.05
2025-12-0818.17
2025-12-0518.54
2025-12-0418.34
2025-12-0318.23
2025-12-0217.97
2025-12-0118.19
2025-11-2818.42
2025-11-2618.51
2025-11-2518.41
2025-11-2418.08
2025-11-2117.99
2025-11-2017.99
2025-11-1918.06
2025-11-1818.06
2025-11-1717.88
2025-11-1417.67
2025-11-1317.52
2025-11-1217.49
2025-11-1117.40
2025-11-1017.20
2025-11-0717.01
2025-11-0617.20
2025-11-0516.96
2025-11-0416.57
2025-11-0316.62
2025-10-3116.88
2025-10-3017.19
2025-10-2917.25
2025-10-2816.21
2025-10-2716.43
2025-10-2416.34
2025-10-2316.64
2025-10-2216.46
2025-10-2116.49
2025-10-2016.89
2025-10-1716.91
2025-10-1616.89
2025-10-1516.87
2025-10-1416.92
2025-10-1317.18
2025-10-1017.17
2025-10-0917.38
2025-10-0817.52
2025-10-0717.83
2025-10-0617.69
2025-10-0317.68
2025-10-0217.31
2025-10-0117.10
2025-09-3016.36
2025-09-2916.56
2025-09-2616.89
2025-09-2516.60
2025-09-2417.13
2025-09-2316.94
2025-09-2216.19
2025-09-1916.30
2025-09-1816.00
2025-09-1715.76
2025-09-1615.53
2025-09-1515.73
2025-09-1215.81
2025-09-1115.80
2025-09-1015.48
2025-09-0915.76
2025-09-0815.40
2025-09-0515.63
2025-09-0414.85
2025-09-0315.28
2025-09-0215.80
2025-08-2911.90
2025-08-2811.99
2025-08-2711.92
2025-08-2612.07
2025-08-2511.92
2025-08-2212.19
2025-08-2112.13
2025-08-2011.96
2025-08-1912.23
2025-08-1812.26
2025-08-1512.22
2025-08-1412.18
2025-08-1312.09
2025-08-1211.76
2025-08-1111.73
2025-08-0811.77
2025-08-0711.69
2025-08-0611.80
2025-08-0511.90
2025-08-0411.42
2025-08-0111.49
2025-07-3110.72
2025-07-3011.01
2025-07-2911.87
2025-07-2811.90
2025-07-2512.15
2025-07-2412.23
2025-07-2312.20
2025-07-2211.89
2025-07-2111.70
2025-07-1811.65
2025-07-1711.86
2025-07-1611.90
2025-07-1511.70
2025-07-1411.88
2025-07-1111.79
2025-07-1011.98
2025-07-0911.99
2025-07-0811.75
2025-07-0711.59
2025-07-0311.75
2025-07-0211.78
2025-07-0111.61
2025-06-3011.47
2025-06-2711.34
2025-06-2611.34
2025-06-2511.41
2025-06-2411.57
2025-06-2311.43
2025-06-2011.60
2025-06-1811.64
2025-06-1711.45
2025-06-1611.51
2025-06-1311.31
2025-06-1211.42
2025-06-1111.03
2025-06-1011.23
2025-06-0913.10
2025-06-0613.00
2025-06-0512.76
2025-06-0412.93
2025-06-0312.94
2025-06-0212.99

Showing the most recent 260 of 4,530 data points. The chart above shows the full history.

Related Metrics

PEG RatioP/B RatioEPSAll Metrics
See the Lowest P/E Ratio Stocks ranking →

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Silver Spring, MD
1,305 employees
www.unither.com
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Martine A. Rothblatt
View full financials